These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 33389407)
1. Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey. Jones S; Hogan B; Patel K; Ooi S; Turton P; Achuthan R; Kim B Breast Cancer Res Treat; 2021 May; 187(1):207-213. PubMed ID: 33389407 [TBL] [Abstract][Full Text] [Related]
2. Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma Trivedi MS; Coe AM; Vanegas A; Kukafka R; Crew KD Cancer Prev Res (Phila); 2017 Aug; 10(8):434-441. PubMed ID: 28611039 [TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD Breast J; 2015; 21(4):377-86. PubMed ID: 25879521 [TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider. Farkas A; Vanderberg R; Merriam S; DiNardo D J Womens Health (Larchmt); 2020 Jan; 29(1):46-56. PubMed ID: 31560601 [TBL] [Abstract][Full Text] [Related]
5. Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. Crew KD Am Soc Clin Oncol Educ Book; 2015; ():e50-8. PubMed ID: 25993215 [TBL] [Abstract][Full Text] [Related]
6. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980 [TBL] [Abstract][Full Text] [Related]
7. Decision making in the context of breast cancer chemoprevention: patient perceptions and the meaning of risk. Holmberg C Am Soc Clin Oncol Educ Book; 2015; ():e59-64. PubMed ID: 25993227 [TBL] [Abstract][Full Text] [Related]
8. What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women? Crew KD Cancer Prev Res (Phila); 2017 Nov; 10(11):609-611. PubMed ID: 28978567 [TBL] [Abstract][Full Text] [Related]
9. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. Aktas B; Sorkin M; Pusztai L; Hofstatter EW Eur J Cancer Prev; 2016 Jan; 25(1):3-8. PubMed ID: 25642790 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Waters EA; Cronin KA; Graubard BI; Han PK; Freedman AN Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):443-6. PubMed ID: 20142242 [TBL] [Abstract][Full Text] [Related]
11. Perceptions of Racially and Ethnically Diverse Women at High Risk of Breast Cancer Regarding the Use of a Web-Based Decision Aid for Chemoprevention: Qualitative Study Nested Within a Randomized Controlled Trial. Jones T; Guzman A; Silverman T; Freeman K; Kukafka R; Crew K J Med Internet Res; 2021 Jun; 23(6):e23839. PubMed ID: 34100769 [TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention. Vogel VG Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712 [TBL] [Abstract][Full Text] [Related]
13. Current concepts in breast cancer chemoprevention. Chlebowski RT Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912 [TBL] [Abstract][Full Text] [Related]
14. Women's views on chemoprevention of breast cancer: qualitative study. Heisey R; Pimlott N; Clemons M; Cummings S; Drummond N Can Fam Physician; 2006 May; 52(5):624-5. PubMed ID: 17327893 [TBL] [Abstract][Full Text] [Related]
15. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634 [TBL] [Abstract][Full Text] [Related]
16. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer. Anderson C; Nichols HB; House M; Sandler DP Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499 [TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Taylor R; Taguchi K Ann Fam Med; 2005; 3(3):242-7. PubMed ID: 15928228 [TBL] [Abstract][Full Text] [Related]
19. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Dunn BK; Ford LG Breast J; 2001; 7(3):144-57. PubMed ID: 11469927 [TBL] [Abstract][Full Text] [Related]
20. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Bychkovsky B; Laws A; Katlin F; Hans M; Knust Graichen M; Pace LE; Scheib R; Garber JE; King TA Breast Cancer Res Treat; 2022 Jun; 193(2):417-427. PubMed ID: 35378642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]